BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11984797)

  • 1. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
    Ramakers-van Woerden NL; Pieters R; Hoelzer D; Slater RM; den Boer ML; Loonen AH; Harbott J; Janka-Schaub GE; Ludwig WD; Ossenkoppele GJ; van Wering ER; Veerman AJ;
    Med Pediatr Oncol; 2002 Jun; 38(6):379-86. PubMed ID: 11984797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype.
    Ramakers-van Woerden NL; Beverloo HB; Veerman AJ; Camitta BM; Loonen AH; van Wering ER; Slater RM; Harbott J; den Boer ML; Ludwig WD; Haas OA; Janka-Schaub GE; Pieters R
    Leukemia; 2004 Mar; 18(3):521-9. PubMed ID: 14712291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
    den Boer ML; Pieters R; Kazemier KM; Rottier MM; Zwaan CM; Kaspers GJ; Janka-Schaub G; Henze G; Creutzig U; Scheper RJ; Veerman AJ
    Blood; 1998 Mar; 91(6):2092-8. PubMed ID: 9490695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
    Valera ET; Scrideli CA; Queiroz RG; Mori BM; Tone LG
    Sao Paulo Med J; 2004 Jul; 122(4):166-71. PubMed ID: 15543372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia.
    Ramakers-van Woerden NL; Pieters R; Loonen AH; Hubeek I; van Drunen E; Beverloo HB; Slater RM; Harbott J; Seyfarth J; van Wering ER; Hählen K; Schmiegelow K; Janka-Schaub GE; Veerman AJ
    Blood; 2000 Aug; 96(3):1094-9. PubMed ID: 10910927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia.
    Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
    Leukemia; 1993 Mar; 7(3):392-7. PubMed ID: 8445945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: relationship with in vitro drug resistance.
    Den Boer ML; Kapaun P; Pieters R; Kazemier KM; Janka-Schaub GE; Veerman AJ
    Br J Haematol; 1999 Jun; 105(4):876-82. PubMed ID: 10554796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Kolodziej B; Rafinska B; Kubicka M; Koltan S; Koltan A; Pogorzala M; Kurylak A; Olszewska-Slonina D; Balwierz W; Juraszewska E; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Malinowska I; Stanczak E; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Maciejka-Kapuscinska L
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):875-93. PubMed ID: 17671794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro resistance of leukaemic blasts to prednisolone in bcr-abl positive childhood acute lymphoblastic leukaemia.
    Gupta M; Kumar A; Dabadghao S
    Indian J Med Res; 2002 Dec; 116():268-72. PubMed ID: 12807155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
    Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
    Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia.
    Den Boer ML; Pieters R; Kazemier KM; Janka-Schaub GE; Henze G; Veerman AJ
    Leukemia; 1999 Dec; 13(12):2023-30. PubMed ID: 10602424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
    Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
    Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
    Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
    Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
    Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
    Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
    Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
    Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
    Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.
    Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
    Leuk Lymphoma; 1995 Nov; 19(5-6):407-16. PubMed ID: 8590840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
    Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
    Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
    Xu B; Song X; Yip NC; Xiao P; Zhang Y; Wang W; Zhou S
    Hematology; 2010 Apr; 15(2):74-80. PubMed ID: 20423567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of bcr-abl-positive acute lymphoblastic leukemia to daunorubicin is not mediated by mdr1 gene expression.
    Gupta M; Kumar A; Dabadghao S
    Am J Hematol; 2002 Nov; 71(3):172-6. PubMed ID: 12410571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.